A medical gadget firm spun out of Northumbria College has reached a big milestone — receiving CE marking for a breath sampling platform that peer-reviewed analysis has demonstrated can reliably accumulate saliva-free exhaled breath condensates (EBC) from the deep lung, making it the primary expertise of its kind to attain this distinction.
PulmoBioMed Ltd has obtained CE marking for its PBM-Hale™ platform, a non-invasive breath sampling gadget developed from analysis carried out at Northumbria College in Newcastle. The CE-marked and US FDA-registered gadget can now be deployed throughout scientific and analysis settings in Europe and the USA and marks a big step ahead within the international effort to make lung illness analysis quicker, safer, and extra accessible to sufferers.
The expertise addresses a problem that has annoyed clinicians for greater than 40 years: easy methods to get hold of dependable samples from the deep lung with out resorting to costly, high-risk invasive procedures. Present gold-standard strategies equivalent to bronchoscopy and bronchoalveolar lavage are reserved for probably the most critically unwell sufferers and can’t be repeated routinely or used at scale in neighborhood settings. Because of this, clinicians are sometimes left treating the signs of lung illness slightly than its underlying causes.
PBM-Hale™ modifications this by enabling the gathering of exhaled breath condensates originating from the deep lung, whereas eliminating contamination from the mouth, higher airways, and the surroundings. The gadget has been efficiently examined in each hospital and first care settings and is designed to work with current diagnostic take a look at workflows.
The expertise was developed throughout Professor Sterghios Moschos’s time as a Professor at Northumbria College, the place his analysis into breath-based diagnostics laid the foundations for what has change into a commercially viable medical gadget. PulmoBioMed was subsequently established as a Northumbria spinout firm, supported by Northern Accelerator — a analysis commercialisation partnership between the North East’s universities — whose Proof-of-Idea funding enabled the event of the primary practical prototype, with speedy prototyping carried out utilizing 3D printers inside Northumbria’s personal engineering labs.
Professor Sterghios A. Moschos, Founder and Chief Govt Officer of PulmoBioMed and Visiting Professor at Northumbria College, mentioned: “Reaching CE marking represents an vital milestone for PulmoBioMed. Our aim has been to handle a 40-year problem in respiratory medication – acquiring dependable samples from the deep lung with out invasive strategies or complicated instrumentation. With regulatory clearance now in place, we look ahead to working with specialist respiratory centres, researchers, and pharmaceutical corporations growing respiratory therapeutics. Our goal is to empower clinically actionable diagnoses that realise personalised respiratory medication.”
Jenny Taylor, Govt Director of Analysis and Innovation Companies at Northumbria College, mentioned: “PulmoBioMed is a superb instance of what occurs when world-class analysis is given the help it wants to achieve its full potential. The CE marking of PBM-Hale™ is a proud second for Northumbria — from Professor Moschos’s early analysis in our labs, via Northern Accelerator’s proof-of-concept help, that is genuinely a North East success story. We look ahead to seeing the expertise make an actual distinction for sufferers and researchers throughout Europe and past.”
The gadget is manufactured underneath contract by Sanner GmbH, a USFDA-registered contract growth and manufacturing organisation (CDMO) based mostly in Germany, whose experience accelerated PulmoBioMed’s journey from prototype to market-ready gadget.
At Sanner, we’re proud to assist flip daring concepts into tangible healthcare options—advancing from first gadget ideas to a sturdy, frozen design and high-quality prototypes. This milestone displays the ability of collaboration and innovation in shaping the way forward for respiratory diagnostics. Congratulations to PulmoBioMed on reaching CE marking for this groundbreaking, dependable, and non-invasive deep lung sampling gadget.”
Stefan Verheyden, CEO at Sanner
PulmoBioMed will now start introducing PBM-Hale™ via structured collaborations with lung transplant centres, diagnostic take a look at producers, analysis establishments, and biotech and pharmaceutical corporations throughout Europe and the USA, with early programmes specializing in settings the place constant entry to deep lung samples might help extra knowledgeable scientific decision-making.
Supply:
Northumbria College, Newcastle
